Country sequencing, vendor geography, and QP release chains are strategic decisions made, well or poorly, at the US IND stage, long before a company believes it is ready to think globally.
White Paper
Designing a Global IND Strategy Before You Think You Need One
Related Resources
All Resources
white-paper
FDA CRLs Reveal a Pattern: Biologic Control Strategy Issues Drive Delays and Rejections
Read More
post
Building the Future of Breakthrough Therapies Together
Read More
post
When the Only Drug Runs Out: Lessons from the Bicillin® L-A Recall
Read More
infographic
Understanding the Stakes of IND Submissions: Why Timely Approvals Matter
Read More
Let's move from science to success.
Let’s Talk